Health Condition 1: null- Those undergoing cataract surgery by standard phacoemulsification and hydrophobic foldable intraocular lens implantation
Conditions
Interventions
Intervention1: ketorolac tromethamine ophthalmic solution) 0.45%: INDICATIONS AND USAGE Ketorolac Tromethamine ophthalmic solution is a nonsteroidal, antiinflammatory indicated for the treatment of pa
sodium bisulfite
sodium chloride
and sodium citrate. The pH during its shelf life ranges from 5.0 - 6.0.
CLINICAL PHARMACOLOGY
Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammat
Sponsors
The Calcutta Medical Research Institute
Allergan India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Uncomplicated cases of Phacoemulsification with IOL implantation. Uncomplicated being defined as a. No capsular dehiscence b. Placement of single piece foldable IOL in the capsular bag c. No sutures applied 2. Includes surgeries where there have been iris handling/trauma (e.g. due to IFIS) or where iris retractors were used 3. Includes surgeries done under GA/Peri-bulbar block/Topical anaesthesia 4. Includes per-operative use of intra-cameral adrenaline and/or trypan blue
Exclusion criteria
Exclusion criteria: 1. Presence of intra-ocular inflammation. 2. History of uveitis â?? anterior/posterior/pan. 3. Rubeosis iridis. 4. Diabetic eye disease including any diabetic retinopathy (even background). 5. History of herpes simplex/HZO (as there may be corneal anaesthesia and subsequent epithelial problems with NSAID therapy). 6. Glaucoma patients on prostaglandin analogue medication. 7. Ocular surface damage secondary to dry eye disease involving staining of the cornea. Conjunctival staining alone is not an exclusion criteria. 8. Use of per-operative intra-cameral antibiotics and/or lignocaine 9. Any intraocular procedure in the last 3 months. 10. Lost to follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anterior segment inflammation PainTimepoint: 1,3 and 5 weeks post surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Cystiod macular oedemaTimepoint: 1,3 and 5 weeks post surgery | — |
Countries
India
Contacts
Public ContactDr Bhaskar Ray Chaudhuri
The Calcutta Medical Research Institute
Outcome results
None listed